Image
Off
BIMZELX: The first and only licensed selective IL-17A and IL-17F inhibitor for moderate-to-severe plaque psoriasis1-3
BIMZELX is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.1
NICE recommendation applies to severe disease (PASI ≥ 10 or DLQI > 10) and when the disease has not responded to other systemic treatments, or when they are contraindicated or not tolerated.2
Off
EXPLORE THE STORIES
Image
Off
Image
Image
Image
Image
Rapidity & durability
Image
Image
DOSING
Image
Image
Safety profile
Off
References
References
- Bimzelx Summary of Product Characteristics.
- National Institute for Health and Care Excellence. 2021. Final Appraisal Document. Bimekizumab for treating moderate to severe plaque psoriasis.
- Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273)487-498.
On
CHALLENGE EXPECTATIONS
Report adverse events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.
Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.
Feature requests
Help us to grow our resource the way you want it to grow.
Date of preparation: August 2021
IE-P-BK-PSO-2100051